Among the takeaway messages from the research:

Even at the lower $349 monthly price for 0.25 mg, 0.5 mg or 1 mg, Ozempic still would take up 5.1% of household income.
Ozempic could consume one-tenth of household income in the lowest-income states. Mississippi (10.1%) leads, followed by West Virginia and Louisiana (both at 9.8%). Conversely, households in the higher-income states of Massachusetts and New Jersey, along with the District of Columbia, spend 5.7% or less.
Ozempic and similar GLP-1 drugs are widely known, with 58% of Americans at least somewhat familiar with them. Nearly 4 in 10 adults currently are using, have used or are considering using these medications. Among those familiar with them, half believe only wealthy people can afford Ozempic or similar drugs for weight loss, while 21% disagree and 28% are neutral.
Among current users, 60% pay $100 or more out of pocket each month for GLP-1 medications. Fifty-eight percent of users who pay out of pocket say they have delayed taking the drug, skipped doses or stopped using their medication because they couldn't afford it.
Insurance coverage could be a gamechanger. Fifty-five percent of consumers who know about GLP-1s, including two-thirds of millennials, say they would be likely to use Ozempic for weight loss if it were fully covered by insurance.

Instant Insights /

Half of Americans believe only the rich can afford GLP-1s without insurance